Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:JAGXNASDAQ:ONCYNASDAQ:SAVANASDAQ:ZFGNNASDAQ:ZSAN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJAGXJaguar Health$0.18+5.9%$0.10$0.05▼$1.22$49.72M1.3550.59 million shs43.55 million shsONCYOncolytics Biotech$1.09+0.9%$1.06$0.88▼$3.39$82.21M1.93367,270 shs219,102 shsSAVACassava Sciences$22.34+2.8%$21.41$12.32▼$32.10$966.21M-0.45769,982 shs1.07 million shsZFGNZafgen$6.44+1.7%$18.47$0.62▼$2.76$241.31M0.27360,199 shs144,013 shsZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJAGXJaguar Health+0.06%-4.01%+146.38%+50.98%-69.09%ONCYOncolytics Biotech+1.89%+4.85%+6.93%-11.48%-14.96%SAVACassava Sciences+4.77%+2.55%+10.25%-10.32%+40.91%ZFGNZafgen-2.01%-0.78%-12.08%+33.83%+40.35%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AONCYOncolytics Biotech1.1219 of 5 stars3.54.00.00.00.60.00.0SAVACassava Sciences3.0999 of 5 stars3.50.00.04.71.70.00.6ZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJAGXJaguar HealthN/AN/AN/AN/AONCYOncolytics Biotech3.00Buy$4.00266.97% UpsideSAVACassava Sciences3.00Buy$124.00455.06% UpsideZFGNZafgenN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest JAGX, SAVA, ONCY, ZFGN, and ZSAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ONCYOncolytics BiotechRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$3.003/5/2024SAVACassava SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$124.002/14/2024ONCYOncolytics BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJAGXJaguar Health$9.76M5.09N/AN/A$0.07 per share2.57ONCYOncolytics BiotechN/AN/AN/AN/A$0.27 per shareN/ASAVACassava SciencesN/AN/AN/AN/A$3.26 per shareN/AZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)ONCYOncolytics Biotech-$20.56M-$0.30N/AN/AN/AN/A-105.97%-72.80%5/3/2024 (Estimated)SAVACassava Sciences-$97.22M-$2.32N/A13.38N/AN/A-57.53%-52.58%5/6/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/AZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest JAGX, SAVA, ONCY, ZFGN, and ZSAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023ONCYOncolytics Biotech-$0.11-$0.04+$0.07-$0.04N/AN/A2/28/2024Q4 2023SAVACassava Sciences-$0.40-$0.50-$0.10-$0.50N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJAGXJaguar HealthN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ASAVACassava SciencesN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJAGXJaguar Health6.332.001.34ONCYOncolytics BiotechN/A9.019.01SAVACassava SciencesN/A9.139.13ZFGNZafgen0.266.566.56ZSANZosano PharmaN/A1.611.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJAGXJaguar Health12.04%ONCYOncolytics Biotech6.82%SAVACassava Sciences38.05%ZFGNZafgen70.43%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipJAGXJaguar Health0.16%ONCYOncolytics Biotech0.10%SAVACassava Sciences9.00%ZFGNZafgen14.20%ZSANZosano Pharma2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableJAGXJaguar Health49276.22 million275.77 millionNo DataONCYOncolytics Biotech2975.42 million75.35 millionNot OptionableSAVACassava Sciences2943.25 million39.35 millionOptionableZFGNZafgen3837.47 millionN/ANot OptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableZSAN, SAVA, JAGX, ONCY, and ZFGN HeadlinesSourceHeadlineHOOK HOOKIPA Pharma Inc.seekingalpha.com - April 12 at 10:11 PMNachrichten - Weitere Nachrichtenwallstreet-online.de - January 9 at 2:39 PMLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planpbs.org - December 6 at 7:44 AMDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abn-tv.de - August 22 at 3:36 PMEast Bay Business Newsbizjournals.com - May 18 at 9:49 PMMankind Pharma IPO opens on April 25, listing scheduled for May 9moneycontrol.com - April 27 at 4:20 PMAstellas Pharmaforbes.com - April 6 at 12:00 PMGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundationfinance.yahoo.com - February 5 at 12:11 PMFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orderswashingtonexaminer.com - January 23 at 3:25 PMZosano Pharma Corporation (ZSANQ)ca.finance.yahoo.com - November 5 at 6:33 PMNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lillyendpts.com - October 13 at 11:22 AMBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giantsmsn.com - October 12 at 2:32 PMBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claimsmarketwatch.com - August 28 at 7:45 PMEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionbizjournals.com - August 27 at 4:10 PMZosano Pharma Corp (ZSANQ)investing.com - August 25 at 12:28 AMEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1Mbizjournals.com - July 26 at 8:27 PMA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.bizjournals.com - July 26 at 8:27 PMZosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8dbtnews.com - June 3 at 11:27 AMZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANmarketwatch.com - June 2 at 3:26 PMWhy Zosano Pharma Shares Are Getting Hammered Todaymsn.com - June 2 at 3:26 PMZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%seekingalpha.com - June 2 at 10:26 AMCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANmarketwatch.com - June 2 at 10:26 AMEast Bay migraine patch developer files for bankruptcybizjournals.com - June 2 at 10:26 AMZosano Pharma Files Voluntary Petition for Relief Under Chapter 11finance.yahoo.com - June 2 at 10:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsJaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.Oncolytics BiotechNASDAQ:ONCYOncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Cassava SciencesNASDAQ:SAVACassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.Zosano PharmaNASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.